Atossa Genetics Inc.
Atossa Genetics Inc. is listed today as Atossa Genetics: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2013 | $1 M | Private placement after listing | Under $2 million | equity | SEC | |
| Apr 2011 | $7 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Atossa Genetics Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2013).
SEC Form D · Apr 2013
The industry group it chose in its notices: Other Health Care.
SEC Form D · Apr 2013
That is all the official record says: Atossa Genetics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Atossa Genetics Inc. are on record.
Investors#
No investor of Atossa Genetics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 156 investors.
Largest shareholders today
Institutions holding Atossa Genetics shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$1 M3.63%
- BlackRock, Inc.$0 M1.69%
- Renaissance Technologies LLC$0 M1.10%
- Geode Capital Management, LLC$0 M0.96%
- Vanguard Fiduciary Trust Co$0 M0.53%
- State Street Corp$0 M0.40%
- UBS Group AG$0 M0.31%
- Ameriprise Financial Inc$0 M0.27%
- Susquehanna International Group, LLP$0 M0.22%
- Northern Trust Corp$0 M0.20%
- Millennium Management LLC$0 M0.15%
- Morgan Stanley$0 M0.12%
- Royal Bank Of Canada$0 M0.05%
- Vanguard Global Advisers, LLC$0 M0.03%
- Barclays PLC$0 M0.03%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kyle C. Guse | Executive officer | Apr 2013 |
| Shu-Chih C. Chen | Executive officer | Apr 2013 |
| Steven C. Quay | Executive officer | Apr 2013 |
| Christopher C. Benjamin | Executive officer | Jun 2011 |
| Alexander C. Cross | Director | Apr 2013 |
| H. Lawrence Remmel | Director | Apr 2013 |
| John C. Barnhart | Director | Apr 2013 |
| Shu-Chih C. Chen | Director | Apr 2013 |
| Stephen C. Galli | Director | Apr 2013 |
| Steven C. Quay | Director | Apr 2013 |
About
Company in Seattle, United States.
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.